Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis

被引:0
作者
Hauser, S. [1 ]
Comi, G. [2 ]
Hartung, H. -P. [3 ]
Selmaj, K. [4 ]
Traboulsee, A. [5 ]
Bar-Or, A. [6 ]
Arnold, D. [6 ]
Klingelschmitt, G. [7 ]
Leppert, D. [8 ]
Kakarieka, A. [8 ]
Lublin, F. [9 ]
Garren, H. [8 ]
Kappos, L. [10 ]
机构
[1] UCSF, Neurosci, San Francisco, CA USA
[2] Sci Inst HS Raffaele, Neurol, Milan, Italy
[3] Univ Dusseldorf, Neurosci, Dusseldorf, Germany
[4] Med Univ Lodz, Neurol, Lodz, Poland
[5] Univ British Columbia, Multiple Sclerosis Clin, Vancouver, BC V5Z 1M9, Canada
[6] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada
[7] F Hoffmann La Roche, Biometr, Basel, Switzerland
[8] F Hoffmann La Roche, Neurosci, Basel, Switzerland
[9] Mt Sinai Hosp, Neurol, New York, NY 10029 USA
[10] Univ Basel Hosp, CH-4031 Basel, Switzerland
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
F3139
引用
收藏
页码:752 / 752
页数:1
相关论文
empty
未找到相关数据